



## Corporate Overview | 2021

TellBio, Inc is a development stage biotechnology company based in Massachusetts, U.S.A. focused on revolutionizing the detection and treatment of cancer through its unique and proprietary circulating tumor cells (CTCs) technology, TellDx, and complementary therapeutics platform, TellRx. Similar to the legend of its namesake William Tell, an expert marksman who delivered his people from a tyrant leader, TellBio's vision is to free patients and their families from the tyranny of cancer via both its TellDx and TellRx platforms.

TellDx, the already fully functional diagnostic solution, detects and isolates live CTCs from patient liquid biopsies. The TellDx platform has been developed and optimized following a decade of R&D investments and is currently deployed as a research tool at several centers of excellence, commercial laboratories, and clinical trials. TellRx is the therapeutics platform that generates novel anti-cancer medicines by specifically characterizing and targeting CTCs. The synergy of these two platforms offers TellBio a unique opportunity to detect viable CTCs via a first-in-class, best-in-class microfluidic diagnostic platform and target CTCs with novel therapeutics to improve outcomes of patients with cancer.

The foundation of the Company's approach, detection of and targeting CTCs, is exclusively licensed from the Massachusetts General Hospital, and is based on decades of academic and clinical research generated by the scientific founders, Daniel Haber, MD, PhD, Mehmet Toner, PhD, David Ting, MD, Shyamala Maheswaran, PhD, and Ravi Kapur, PhD. TellBio was founded in 2019 by biotechnology industry veteran and entrepreneur, Richard Peters, MD, PhD.

TellBio recently hired an executive leadership team including Pritesh J. Gandhi as CEO and Annie Partisano as SVP and Head of Operations.

